Compare BWXT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWXT | CORT |
|---|---|---|
| Founded | 1867 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 7.6B |
| IPO Year | N/A | N/A |
| Metric | BWXT | CORT |
|---|---|---|
| Price | $174.85 | $88.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $183.45 | $139.00 |
| AVG Volume (30 Days) | ★ 1.1M | 663.7K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | ★ 10.60 | N/A |
| EPS | ★ 3.34 | 0.87 |
| Revenue | ★ $3,058,850,000.00 | $741,172,000.00 |
| Revenue This Year | $18.91 | $23.79 |
| Revenue Next Year | $16.08 | $40.97 |
| P/E Ratio | ★ $52.41 | $99.75 |
| Revenue Growth | 14.01 | ★ 17.92 |
| 52 Week Low | $84.21 | $49.00 |
| 52 Week High | $218.50 | $117.33 |
| Indicator | BWXT | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 68.54 |
| Support Level | $172.25 | $81.31 |
| Resistance Level | $183.94 | $87.19 |
| Average True Range (ATR) | 5.65 | 2.86 |
| MACD | 0.87 | 0.74 |
| Stochastic Oscillator | 36.56 | 93.81 |
BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.